77 related articles for article (PubMed ID: 38408959)
1. PTBP3 promotes malignancy and hypoxia-induced chemoresistance in pancreatic cancer cells by ATG12 up-regulation.
Ma J; Weng L; Jia Y; Liu B; Wu S; Xue L; Yin X; Mao A; Wang Z; Shang M
J Cell Mol Med; 2020 Mar; 24(5):2917-2930. PubMed ID: 31989778
[TBL] [Abstract][Full Text] [Related]
2. IFN‑γ induces apoptosis in gemcitabine‑resistant pancreatic cancer cells.
Kong X; Cheng D; Xu X; Zhang Y; Li X; Pan W
Mol Med Rep; 2024 May; 29(5):. PubMed ID: 38488034
[TBL] [Abstract][Full Text] [Related]
3. CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer.
Tuerhong A; Xu J; Wang W; Shi S; Meng Q; Hua J; Liu J; Zhang B; Yu X; Liang C
Surgery; 2024 May; 175(5):1264-1275. PubMed ID: 38302326
[TBL] [Abstract][Full Text] [Related]
4. CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma.
Cheng K; Zhou Z; Chen Q; Chen Z; Cai Y; Cai H; Wu S; Gao P; Cai Y; Zhou J; Wang X; Wu Z; Peng B
Sci Rep; 2024 Apr; 14(1):8389. PubMed ID: 38600093
[TBL] [Abstract][Full Text] [Related]
5. Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer.
Yang J; Xu J; Zhang B; Tan Z; Meng Q; Hua J; Liu J; Wang W; Shi S; Yu X; Liang C
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681603
[TBL] [Abstract][Full Text] [Related]
6. Differential Sensitivity to Ionizing Radiation in Gemcitabine-Resistant and Paclitaxel-Resistant Pancreatic Cancer Cells.
Che PP; Gregori A; Bergonzini C; Ali M; Mantini G; Schmidt T; Finamore F; Rodrigues SMF; Frampton AE; McDonnell LA; Danen EH; Slotman BJ; Sminia P; Giovannetti E
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1328-1343. PubMed ID: 37914140
[TBL] [Abstract][Full Text] [Related]
7. Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathways.
Miao X; Koch G; Shen S; Wang X; Li J; Shen X; Qu J; Straubinger RM; Jusko WJ
J Pharm Sci; 2024 Jan; 113(1):235-245. PubMed ID: 37918792
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic Cancer Chemoresistance to Gemcitabine.
Amrutkar M; Gladhaug IP
Cancers (Basel); 2017 Nov; 9(11):. PubMed ID: 29144412
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological activity of 11-Oxygenated and heterocyclic estrone analogs in pancreatic cancer monolayers and 3D spheroids.
Alseud K; Ostlund T; Durymanov M; Reineke J; Halaweish F
Bioorg Med Chem; 2024 Apr; 103():117678. PubMed ID: 38489997
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine Modulates HLA-I Regulation to Improve Tumor Antigen Presentation by Pancreatic Cancer Cells.
Larson AC; Knoche SM; Brumfield GL; Doty KR; Gephart BD; Moore-Saufley PR; Solheim JC
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542184
[TBL] [Abstract][Full Text] [Related]
11. Huaier enhances the tumor-killing effect and reverses gemcitabine-induced stemness by suppressing FoxM1.
Wang Q; Gong M; Liu R; Mo J; Bai R; An R; Wang X; Han L; Wang Z; Ma Q; Wu Z; Zhou C
Phytomedicine; 2024 Jul; 129():155656. PubMed ID: 38723529
[TBL] [Abstract][Full Text] [Related]
12. APOBEC3 upregulation drives gemcitabine resistance.
Maciejowski J; Mohamed T
Nat Cancer; 2024 May; ():. PubMed ID: 38778178
[No Abstract] [Full Text] [Related]
13. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
14. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
Gordon ER; Wright CA; James M; Cooper SJ
BMC Cancer; 2023 Jun; 23(1):524. PubMed ID: 37291514
[TBL] [Abstract][Full Text] [Related]
15. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine resistance in pancreatic ductal adenocarcinoma.
Binenbaum Y; Na'ara S; Gil Z
Drug Resist Updat; 2015 Nov; 23():55-68. PubMed ID: 26690340
[TBL] [Abstract][Full Text] [Related]
17. Barriers and opportunities for gemcitabine in pancreatic cancer therapy.
Beutel AK; Halbrook CJ
Am J Physiol Cell Physiol; 2023 Feb; 324(2):C540-C552. PubMed ID: 36571444
[TBL] [Abstract][Full Text] [Related]
18. EGR1 mediates MDR1 transcriptional activity regulating gemcitabine resistance in pancreatic cancer.
Yang Z; Chen F; Wei D; Chen F; Jiang H; Qin S
BMC Cancer; 2024 Feb; 24(1):268. PubMed ID: 38408959
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]